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We have used antibody (MAb) specific to hypoglycosy-
lated tumor associated MUC1 as a strategy to induce
tumor specific immunity. Xenotypic IgG1 has been pre-
viously shown to induce T cell immunity targeting MUC1
in patients. We now describe MUC1 specific IgE to repro-
gram myeloid cells in the tumor microenvironment and
modulate tumor specific immunity.
To test if these MAb mediate rejection of mouse breast
cancer cells transfected with human MUC1 (4T-1/
hMUC1), we injected MAb peritumorally for 5 days after
sc tumor inoculation. These experiments were performed
in mice with mFcεRI deleted, and transgenic for the coun-
terpart human receptor (hFcεRI). We observed modest
differences in the tumor growth rates after injection of
hMUC1 IgE compared to a non-specific hIgE antibody.
Analysis of the treated tumors showed solid sheets of
tumor cells without the presence of effector cells of the
allergic response.
Since MUC1 is a “neutral” antigen, and does not trans-
mit a growth signal, we speculated that the antibodies
modest activity was due to the absence of bone marrow
derived cells in the microenvironment. Furthermore, the
mice generated mouse anti-human IgE (MAHA) antibo-
dies after two weeks. Accordingly, we engineered a 4T-1
tumor cell line that produced mouse IgE specific for
hMUC1 (mIgE hMUC1). We also engineered other 4T-1
cells to produce hMUC1 and cytokines to draw myeloid
cells into the tumor microenvironment. Cell mixing
experiments were performed to bring together mIgE, the
antigen (hMUC1) and the cytokines (IL-5 and MCP-1).
These experiments, performed in KO/Tg animals,
showed complete rejection of tumors in which MAb,
antigen, and myeloid effector cells are brought together.
If one of these elements were left out, the tumors grew
progressively. We also observed that the presence of the
two cytokines (IL-5, MCP-1) caused 4T-1 cells to metas-
tasize early after injection.
To test if complete tumor rejection could only be
observed in our KO/Tg mice, we repeated the cell mixing
experiments in wild type Balb/c mice. In mixing experi-
ments that brought together the antibody (anti-hMUC1
mIgE), the antigen (hMUC1) and the cytokines (IL-5/
MCP-1), we observed slow growth of the tumors in Balb/c
mice, suggesting that the expanded spectrum of expression
of the hFcεRI was crucial for the complete elimination of
the tumors from these KO/Tg mice. The presence of the
IgE antibody reversed the “early metastases” phenotype
conferred by the cytokines. Tumor antigen specific IgE is a
promising approach for reprogramming myeloid cells in
the tumor microenvironment, leading to elimination of
tumors, and reversal of the cytokine-conferred metastatic
phenotype. These antibodies may also be useful for aug-
menting host tumor immunity.
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